Fig. 3
From: Allicin induced AMPK signaling attenuated Smad3 pathway mediated lung fibrosis
Effect of allicin on a mouse model of BLM-induced lung fibrosis. Allicin was administrated from day 16 to 20 after intratracheal injection of BLM (a). Changes in body weight after BLM treatment. Body weight was defined as 0 on day 14 (after BLM treatment) (b). Concentrations of inflammatory cells (total cells, macrophages, lymphocytes, and neutrophils) in the bronchoalveolar lavage fluid of mice in each group. Cells were counted using a manual hemocytometer (c). Masson’s trichrome and hematoxylin and eosin staining of specimens from mice lungs harvested on day 22 at 40 × and 200× magnification. Scale bars represent 500 μm and 100 μm, respectively. Immunohistochemical analysis of phospho-SMAD3 in mouse lungs. Scale bar = 500 μm. (d) Ashcroft score for each group of five mice (e). Phospho-SMAD3-positive cells were counted in 10 fields at ×200 magnification. The average percentage of phospho-SMAD3-positive cells in each of the four groups was calculated by dividing the average for each group with that of the control group (f). Data were assessed using one-way analysis of variance and are presented as mean ± SEM. *P < 0.05.
